多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效分析

Efficacy of Docetaxel Combined Cisplatin in TreatmentingAdvanced Nonsmall Cell Lung Cancer

目的：探讨多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效。方法：对我院2009年1月~2010年6月收治的43例晚期非小细胞肺癌患者使用多西他赛联合顺铂进行治疗。其中多西他赛于第一日给予1次,每次75mg/m2,顺铂每（1~3）日给予1次,每次25mg/m2。每21日为一个周期,观察患者经过2个周期的治疗后的治疗效果及不良反应的发生。结果：43例患者经过治疗后,2例患者完全缓解,16例患者部分缓解,19例患者无明显变化,6例患者病情进展。其总有效率为51.16%。患者主要的不良反应为骨髓抑制。结论：采用多西他赛联合顺铂治疗晚期非小细胞肺癌可取得较好的疗效,患者不良反应轻,值得在临床推广。

Objective：To investigate docetaxel in combination with cisplatin for treatment of advanced non-small cell lung cancer.Methods：The hospital in January 2009-June 2010 were treated 43 patients with advanced non-small cell lung cancer patients with docetaxel and cisplatin treatment.In which docetaxel was given the first day 1,each 75mg /m 2,each cisplatin（1-3） to give 1 day,each 25mg /m 2.Every 21 day cycle,patients were observed after 2 cycles of treatment and after treatment,the incidence of adverse reactions.Results：43 patients after treatment,2 patients complete remission,partial remission in 16 patients,no significant changes in 19 patients,6 patients with disease progression.The total effective rate was 51.16%.The main adverse events in patients with bone marrow suppression.Conclusion：Docetaxel and cisplatin treatment of advanced non-small cell lung cancer can achieve better efficacy,adverse reactions in patients,it is worth in clinical practice.